Biogen

News

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

Biogen's efforts to defend its SMA business have been dealt a setback after the FDA declined to approve a high-dose version of Spinraza.

News

Biogen buys Alcyone, bringing a partnered technology for delivery of antisense drugs into the central nervous system in-house.

News

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

Germany and Austria are the first countries in the EU to see the launch of Leqembi, Eisai and Biogen's much-delayed treatment for Alzheimer's.